1 Metric to Watch for Celsius Holdings Stock in 2025

Celsius Holdings (CELH) shares climbed 43% following its Q2 2025 earnings report, driven by an 84% year-over-year surge in net sales to over $739 million. This substantial growth was primarily fueled by the Alani Nu acquisition, which saw 129% sales growth, significantly outpacing the core Celsius brand's 9% increase. Despite a 107% rise in selling, general, and administrative expenses, the company expanded its U.S. market share by 1.8 percentage points to 17.3%, highlighting the acquisition's critical impact and the ongoing importance of its PepsiCo distribution partnership for sustained revenue momentum.

Analysis

Celsius Holdings (CELH) has reported a significant 84% year-over-year increase in Q2 2025 net sales to over $739 million, fueling a 43% rally in its stock price. However, this top-line growth is heavily skewed by the recent acquisition of Alani Nu, which saw its brand sales surge 129%. In contrast, the core Celsius brand's organic sales growth was a comparatively modest 9% year-over-year. While the acquisition has successfully expanded the company's U.S. market share by 1.8 percentage points to 17.3%, it has also driven a 107% increase in selling, general, and administrative expenses due to integration costs and higher marketing spend. This highlights a critical dynamic: while inorganic growth has re-accelerated revenue, it has come at a significant cost and masks a substantial deceleration in the core business. The company's reliance on its distribution partnership with PepsiCo remains a crucial factor for sustained momentum, as past slowdowns from this partner have previously led to sharp stock price declines.

Key Decisions for Investors

• Investors should scrutinize the organic growth rate of the core Celsius brand in subsequent reports, as the headline sales figures are currently inflated by the Alani Nu acquisition.
• Monitor selling, general, and administrative expenses closely, as the 107% increase signals a potential threat to future profitability and margin expansion.
• The health of the PepsiCo distribution partnership is a critical dependency; any signs of weakening sell-through or changes in this relationship present a material risk to the investment thesis.
• Given the stock's 43% post-earnings appreciation, consider whether the current valuation adequately reflects the risks associated with slowing organic growth and rising operational costs.